Implications of new oral anticoagulants for stroke prophylaxis in elderly patients with atrial fibrillation

Jonathan L. Halperin, Jotinder K. Malhotra

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


The prevalence of atrial fibrillation (AF) increases with age and is projected to escalate in coming decades as people have longer life expectancies. The burden of this disease has a substantial impact on healthcare costs and quality of life, particularly among AF patients who experience strokes. Until recently, the mainstays of stroke prophylaxis in patients with AF have been anticoagulation with warfarin or antiplatelet therapy with aspirin, depending on patient preferences, clinical risk stratification, and contraindications. However, the limitations of these conventional options, especially among elderly patients, have given rise to the first new oral anticoagulants in over half a century. Successful clinical trials have led to regulatory approval of several alternatives for clinical use. This article reviews the evidence supporting antithrombotic prophylaxis, describes current practice guidelines, and discusses the use of novel therapeutic options for elderly patients with nonvalvular AF.

Original languageEnglish
Pages (from-to)28-33
Number of pages6
JournalAnnals of Long-Term Care
Issue number5
StatePublished - May 2014


  • Anticoagulants
  • Antiplatelet agents
  • Antithrombotic prophylaxis
  • Atrial fibrillation
  • Nonvalvular atrial fibrillation
  • Stroke


Dive into the research topics of 'Implications of new oral anticoagulants for stroke prophylaxis in elderly patients with atrial fibrillation'. Together they form a unique fingerprint.

Cite this